EUVIMEDEUVIMED entdecken
Crossref

Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization

Jessica L Sheehan iD, Dala Eloubeidi, Kira L Newman, Laura A Johnson, Ariel A Jordan, Shirley Cohen-Mekelburg iD, Jeffrey A Berinstein, Renuka Tipirneni iD, Peter D R Higgins iD

Inflammatory Bowel Diseases · 01.09.2026 · 32 (9) · 1741-1749

DOI: 10.1093/ibd/izag062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 25.04.2026. Verfasst von Jessica L Sheehan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, United States. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Patient Acceptance of Health Care, Biological Products, Drug Monitoring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Gefördert von: T32, AbbVie, Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Biologic persistence, defined as the total uninterrupted time on a biologic agent, is associated with improved outcomes in inflammatory bowel disease (IBD). However, social determinants of health (SDOH), such as socioeconomic status, may influence a patient’s ability to access these medications. We aimed to better understand the relationship between socioeconomic status and biologic persistence in patients with IBD and to determine whether patients with poor biologic persistence had higher health care utilization.

Methods

We identified patients with IBD seen at the University of Michigan during 2015-2022. Using the Centers for Disease Control Social Vulnerability Index (SVI), we examined the relationship between socioeconomic status and biologic persistence, defined as an active biologic prescription for 365 days or longer, while controlling a priori for IBD type, age, sex, race, comorbidities, IBD severity, and insurance type. Secondarily, we examined the relationship between biologic persistence and unplanned health care utilization.

Results

In this cohort of 3067 patients with IBD who were prescribed biologics, 20% (n = 620) did not achieve biologic persistence. Low socioeconomic status (odds ratio [OR] 0.56; P = .003) was associated with a lower likelihood of achieving biologic persistence. Biologic persistence was associated with lower risk of IBD-related hospitalization (incidence rate ratio [IRR], 0.48; P < .001), readmission (IRR, 0.52; P < .001), and surgery (IRR, 0.33; P < .001).

Conclusions

Low socioeconomic status was associated with lower likelihood of biologic persistence and patients who lacked biologic persistence had greater IBD-related unplanned health care utilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesPatient Acceptance of Health CareBiological ProductsDrug MonitoringHumansFemaleMaleAdultSocioeconomic Disparities in HealthMiddle AgedMichigan

Stichwörter der Autor:innen

Crohn diseasebiologic persistencehealth disparitiessocial determinants of healthulcerative colitis

Substanzen

Biological Products

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, Michigan Medicine, Ann Arbor, MI, United States.
  • Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Alabama Birmingham, Birmingham, AL, United States.
  • Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, United States.
  • VA Center for Clinical Management Research, VA Ann Arbor Health Care System, Ann Arbor, MI, United States.
  • Department of Internal Medicine, Michigan Medicine, Ann Arbor, MI, United States.

ORCID-Profile: Jessica L Sheehan, Shirley Cohen-Mekelburg, Renuka Tipirneni, Peter D R Higgins

Förderung

  • T32
  • AbbVie
  • Pfizer
  • Blue Cross Blue Shield of Michigan
  • Michigan Department of Health & Human Services
  • The Commonwealth Fund

Zitieren

APA

Sheehan, J. L., Eloubeidi, D., Newman, K. L., Johnson, L. A., Jordan, A. A., Cohen-Mekelburg, S., Berinstein, J. A., Tipirneni, R., & Higgins, P. D. R. (2026). Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization. Inflammatory Bowel Diseases, 32(9), 1741-1749. https://doi.org/10.1093/ibd/izag062

Vancouver

Sheehan JL, Eloubeidi D, Newman KL, Johnson LA, Jordan AA, Cohen-Mekelburg S, et al. Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization. Inflammatory Bowel Diseases. 2026;32(9):1741-1749. doi:10.1093/ibd/izag062

BibTeX
@article{Sheehan2026,
  author = {Sheehan, Jessica L and Eloubeidi, Dala and Newman, Kira L and Johnson, Laura A and Jordan, Ariel A and Cohen-Mekelburg, Shirley and Berinstein, Jeffrey A and Tipirneni, Renuka and Higgins, Peter D R},
  title = {Socioeconomic disparities in biologic persistence among patients with inflammatory bowel disease are associated with increased health care utilization},
  journal = {Inflammatory Bowel Diseases},
  year = {2026},
  volume = {32},
  number = {9},
  pages = {1741--1749},
  doi = {10.1093/ibd/izag062}
}
Kostenlos starten →